介素-1受体辅助蛋白 (IL-1RAP):人类恶性瘤免疫治疗的魔法子弹候选人
Ali Zarezadeh Mehrabadi1, Faezeh Shahba1, Hossein Khorramdelazad2
1Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Critical reviews in oncology/hematology
|November 19, 2023
概括
介素-1受体辅助蛋白 (IL-1RAP) 在各种固体和血液恶性瘤的癌症进展,血管生成和转移中至关重要. 向IL-1RAP是一个有前途的癌症治疗新疗法策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 介质素-1 (IL-1) 是一种促炎性细胞因子,涉及病理性炎症,瘤发生和瘤微环境 (TME).
- IL-1受体辅助蛋白 (IL-1RAP),与IL-1受体-1一起,形成了IL-1信号传递的功能综合体.
- 已经证明IL-1RAP在各种固体瘤和血液恶性瘤的进展,血管生成和转移中起着重要作用.
研究的目的:
- 审查IL-1RAP在各种癌症类型中的多方面的作用.
- 探索针对IL-1RAP作为恶性瘤的新疗法策略的潜力.
主要方法:
- 对研究IL-1RAP在癌症中的研究的文献综述.
- 分析IL-1RAP与FLT-3,c-Kit和SLC3A2.2.等其他分子的相互作用.
- 关于IL-1RAP参与癌症病原和治疗向的概述.
主要成果:
- IL-1RAP与胃肠道瘤,肺癌,质瘤,乳腺癌和宫癌的进展,血管生成和转移有关.
- IL-1RAP与铁氨酸激酶FLT-3和c-Kit相互作用,导致急性髓性淋巴瘤等血液恶性瘤.
- IL-1RAP与SLC3A2的相互作用增强了阿诺基斯的抵抗力和尤宁肉瘤的转移.
结论:
- IL-1RAP在各种癌症的发展和传播中起着至关重要的作用.
- 准IL-1RAP为新型癌症疗法提供了一个有希望的途径.
更多相关视频
08:30Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
Published on: May 10, 2022
2.0K
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
14.8K
相关概念视频
01:27Tumor Immunotherapy
530
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
530
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K